Research Impact Award Results
2022
Funding Rate = 38.5%
| Name | LKSIoV Supervisor | Amount | Title of Published Article |
|---|---|---|---|
| Daniel Limonta | Tom C. Hobman | $1,000 | Nodosome inhibition as a novel broad-spectrum antiviral strategy against arboviruses, enteroviruses, and SARS-CoV-2 |
| Ghazal Babolmorad | Amit. P. Bhavsar | $1,000 | Toll-like receptor 4 is activated by platinum and contributes to cisplatin-inducedototoxicity |
| Lee K. Campbell | Katharine E. Magor | $1,000 | Tissue specific transcriptome changes upon influenza A virus replication in the duck |
| Meng Zhao | Michael T. Woodside | $1,000 | Mechanical strength of RNA knot in Zika virus protects against cellular defenses |
| Shima Shabaz | Shokrollah Elahi | $1,000 | Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2 |
| TOTAL | $5,000 |
Meet each of our 2022 awardees and read about their publication
Research Impact Awards 2021
Funding Rate = 67%
| Name | LKSIoV Supervisor | Amount | Title of Published Article |
|---|---|---|---|
| Brittany Umer | David Evans | $1,000 | Deciphering the immunomodulatory capacity of oncolytic vaccinia virus to enhance the immune response to breast cancer |
| Calvin Gordon | Matthias Götte | $1,000 | Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency |
| Cameron Griffiths | David Marchant | $1,000 | IGF1R is an entry receptor for respiratory syncytial virus |
| Shima Shabaz | Shokrollah Elahi | $1,000 | Galectin-9 and VISTA expression define terminally exhausted T cells in HIV-1 infection |
| TOTAL | $4,000 |